Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

Hernan Carol, Richard Lock, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background. Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. Ispinesib was tested against the PPTP in vitro panel cell lines at concentrations from 0.1 nM to 1 mM and against the in vivo tumor panel xenografts by intraperitoneal administration (5 or 10 mg/kg) every 4 days for 3 doses repeated at day 21. Results. Ispinesib was highly potent against the PPTP's in vitro cell lines with a median IC50 of 4.1 nM. Ispinesib (10 mg/kg) induced unexplained toxicity in mice bearing osteosarcoma xenografts and exceeded the MTD in 12 of 40 non-osteosarcoma xenografts. Ispinesib induced significant tumor growth delay in 88% (23/26) of evaluable xenografts. Using a time to event measure of efficacy, ispinesib had intermediate and high levels of activity against 4 (21%) and 5 (26%) of the 19 evaluable solid tumor xenografts, respectively. Ispinesib induced maintained complete responses (CR) in a rhabdoid tumor, a Wilms tumor and a Ewing sarcoma xenograft. Ispinesib (5 mg/kg) produced 2 complete and 2 partial responses among 6 evaluable xenografts in the ALL panel. The in vivo pattern of activity was distinctive from that previously reported for vincristine. Conclusions. Ispinesib demonstrated broad in vivo antitumor activity, including maintained complete responses for several xenografts, although with high toxicity rates at the doses studied.

Original languageEnglish (US)
Pages (from-to)1255-1263
Number of pages9
JournalPediatric Blood and Cancer
Volume53
Issue number7
DOIs
StatePublished - Dec 15 2009

Fingerprint

Kinesin
Heterografts
Pediatrics
Proteins
ispinesib
Rhabdoid Tumor
Spindle Poles
Cell Line
Neoplasms
Ewing's Sarcoma
Wilms Tumor
Vincristine
Osteosarcoma
Inhibitory Concentration 50

Keywords

  • Developmental therapeutics
  • Ispinesib
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Carol, H., Lock, R., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., ... Smith, M. A. (2009). Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 53(7), 1255-1263. https://doi.org/10.1002/pbc.22056

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. / Carol, Hernan; Lock, Richard; Houghton, Peter J.; Morton, Christopher L.; Kolb, E. Anders; Gorlick, Richard; Reynolds, C. Patrick; Maris, John M.; Keir, Stephen T.; Billups, Catherine A.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 53, No. 7, 15.12.2009, p. 1255-1263.

Research output: Contribution to journalArticle

Carol, H, Lock, R, Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Reynolds, CP, Maris, JM, Keir, ST, Billups, CA & Smith, MA 2009, 'Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 53, no. 7, pp. 1255-1263. https://doi.org/10.1002/pbc.22056
Carol, Hernan ; Lock, Richard ; Houghton, Peter J. ; Morton, Christopher L. ; Kolb, E. Anders ; Gorlick, Richard ; Reynolds, C. Patrick ; Maris, John M. ; Keir, Stephen T. ; Billups, Catherine A. ; Smith, Malcolm A. / Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 7. pp. 1255-1263.
@article{a8a9fcd65cac4b8aa251d566ca27827c,
title = "Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program",
abstract = "Background. Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. Ispinesib was tested against the PPTP in vitro panel cell lines at concentrations from 0.1 nM to 1 mM and against the in vivo tumor panel xenografts by intraperitoneal administration (5 or 10 mg/kg) every 4 days for 3 doses repeated at day 21. Results. Ispinesib was highly potent against the PPTP's in vitro cell lines with a median IC50 of 4.1 nM. Ispinesib (10 mg/kg) induced unexplained toxicity in mice bearing osteosarcoma xenografts and exceeded the MTD in 12 of 40 non-osteosarcoma xenografts. Ispinesib induced significant tumor growth delay in 88{\%} (23/26) of evaluable xenografts. Using a time to event measure of efficacy, ispinesib had intermediate and high levels of activity against 4 (21{\%}) and 5 (26{\%}) of the 19 evaluable solid tumor xenografts, respectively. Ispinesib induced maintained complete responses (CR) in a rhabdoid tumor, a Wilms tumor and a Ewing sarcoma xenograft. Ispinesib (5 mg/kg) produced 2 complete and 2 partial responses among 6 evaluable xenografts in the ALL panel. The in vivo pattern of activity was distinctive from that previously reported for vincristine. Conclusions. Ispinesib demonstrated broad in vivo antitumor activity, including maintained complete responses for several xenografts, although with high toxicity rates at the doses studied.",
keywords = "Developmental therapeutics, Ispinesib, Preclinical testing",
author = "Hernan Carol and Richard Lock and Houghton, {Peter J.} and Morton, {Christopher L.} and Kolb, {E. Anders} and Richard Gorlick and Reynolds, {C. Patrick} and Maris, {John M.} and Keir, {Stephen T.} and Billups, {Catherine A.} and Smith, {Malcolm A.}",
year = "2009",
month = "12",
day = "15",
doi = "10.1002/pbc.22056",
language = "English (US)",
volume = "53",
pages = "1255--1263",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

AU - Carol, Hernan

AU - Lock, Richard

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Reynolds, C. Patrick

AU - Maris, John M.

AU - Keir, Stephen T.

AU - Billups, Catherine A.

AU - Smith, Malcolm A.

PY - 2009/12/15

Y1 - 2009/12/15

N2 - Background. Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. Ispinesib was tested against the PPTP in vitro panel cell lines at concentrations from 0.1 nM to 1 mM and against the in vivo tumor panel xenografts by intraperitoneal administration (5 or 10 mg/kg) every 4 days for 3 doses repeated at day 21. Results. Ispinesib was highly potent against the PPTP's in vitro cell lines with a median IC50 of 4.1 nM. Ispinesib (10 mg/kg) induced unexplained toxicity in mice bearing osteosarcoma xenografts and exceeded the MTD in 12 of 40 non-osteosarcoma xenografts. Ispinesib induced significant tumor growth delay in 88% (23/26) of evaluable xenografts. Using a time to event measure of efficacy, ispinesib had intermediate and high levels of activity against 4 (21%) and 5 (26%) of the 19 evaluable solid tumor xenografts, respectively. Ispinesib induced maintained complete responses (CR) in a rhabdoid tumor, a Wilms tumor and a Ewing sarcoma xenograft. Ispinesib (5 mg/kg) produced 2 complete and 2 partial responses among 6 evaluable xenografts in the ALL panel. The in vivo pattern of activity was distinctive from that previously reported for vincristine. Conclusions. Ispinesib demonstrated broad in vivo antitumor activity, including maintained complete responses for several xenografts, although with high toxicity rates at the doses studied.

AB - Background. Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. Ispinesib was tested against the PPTP in vitro panel cell lines at concentrations from 0.1 nM to 1 mM and against the in vivo tumor panel xenografts by intraperitoneal administration (5 or 10 mg/kg) every 4 days for 3 doses repeated at day 21. Results. Ispinesib was highly potent against the PPTP's in vitro cell lines with a median IC50 of 4.1 nM. Ispinesib (10 mg/kg) induced unexplained toxicity in mice bearing osteosarcoma xenografts and exceeded the MTD in 12 of 40 non-osteosarcoma xenografts. Ispinesib induced significant tumor growth delay in 88% (23/26) of evaluable xenografts. Using a time to event measure of efficacy, ispinesib had intermediate and high levels of activity against 4 (21%) and 5 (26%) of the 19 evaluable solid tumor xenografts, respectively. Ispinesib induced maintained complete responses (CR) in a rhabdoid tumor, a Wilms tumor and a Ewing sarcoma xenograft. Ispinesib (5 mg/kg) produced 2 complete and 2 partial responses among 6 evaluable xenografts in the ALL panel. The in vivo pattern of activity was distinctive from that previously reported for vincristine. Conclusions. Ispinesib demonstrated broad in vivo antitumor activity, including maintained complete responses for several xenografts, although with high toxicity rates at the doses studied.

KW - Developmental therapeutics

KW - Ispinesib

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=70449728074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449728074&partnerID=8YFLogxK

U2 - 10.1002/pbc.22056

DO - 10.1002/pbc.22056

M3 - Article

C2 - 19554570

AN - SCOPUS:70449728074

VL - 53

SP - 1255

EP - 1263

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -